Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection |
Park, Hyun-Kyung
(Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
Lee, Dong-Ho (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Suh, Seung-Chul (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Seo, Pyoung-Ju (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Kim, Na-Young (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Jeong, Sook-Hyang (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Kim, Jin-Wook (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Hwang, Jin-Hyeok (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Park, Young-Soo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Lee, Sang-Hyub (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) Shin, Cheol-Min (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) |
1 | Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186. DOI ScienceOn |
2 | Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. DOI ScienceOn |
3 | Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006;48:156-161. |
4 | Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170-175. |
5 | Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009;14:77-85. |
6 | Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62. |
7 | Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-319. DOI ScienceOn |
8 | Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395-403. DOI ScienceOn |
9 | Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. DOI ScienceOn |
10 | Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057. DOI ScienceOn |
11 | Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283-285. DOI ScienceOn |
12 | Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002;49:1039-1040. DOI ScienceOn |
13 | Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol 2006;47:337-349. |
14 | Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94. DOI ScienceOn |
15 | Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316. DOI ScienceOn |
16 | Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-1499. |
17 | Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001;15:143. DOI ScienceOn |
18 | Bayerdörffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-1417. DOI ScienceOn |
19 | Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdörffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323-329. DOI ScienceOn |
20 | Lamouliatte H, Cayla R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. Am J Gastroenterol 1998;93:1531-1534. DOI ScienceOn |
21 | Westblom TU, Duriex DE. Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections. Dig Dis Sci 1991;36:25-28. DOI ScienceOn |
22 | Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-461. DOI ScienceOn |
23 | Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19:789-795. DOI ScienceOn |
24 | Nam TM, Lee DH, Kang KP, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc 2008;36:200-205. |
25 | Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384. DOI ScienceOn |
26 | Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-654. DOI ScienceOn |
27 | Keum B, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol 2005;46:433-439. |
28 | de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000;320:31-34. DOI ScienceOn |
29 | Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003;35:357-361. DOI ScienceOn |
30 | Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001;15:1543-1547. DOI ScienceOn |
31 | Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000;14:1335-1338. DOI ScienceOn |
![]() |